Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 136

1.

The association of race, sociodemographic, and behavioral characteristics with response to highly active antiretroviral therapy in women.

Anastos K, Schneider MF, Gange SJ, Minkoff H, Greenblatt RM, Feldman J, Levine A, Delapenha R, Cohen M; Women's Interagency HIV Study Collaborative Group.

J Acquir Immune Defic Syndr. 2005 Aug 15;39(5):537-44.

PMID:
16044004
2.

The prognostic importance of changes in CD4+ cell count and HIV-1 RNA level in women after initiating highly active antiretroviral therapy.

Anastos K, Barrón Y, Cohen MH, Greenblatt RM, Minkoff H, Levine A, Young M, Gange SJ.

Ann Intern Med. 2004 Feb 17;140(4):256-64.

PMID:
14970148
3.

Gender differences in HIV-1 RNA rebound attributed to incomplete antiretroviral adherence among HIV-Infected patients in a population-based cohort.

Kuyper LM, Wood E, Montaner JS, Yip B, O'connell JM, Hogg RS.

J Acquir Immune Defic Syndr. 2004 Dec 1;37(4):1470-6.

PMID:
15602125
4.

Prevalence and predictors of highly active antiretroviral therapy use in patients with HIV infection in the united states. HCSUS Consortium. HIV Cost and Services Utilization.

Cunningham WE, Markson LE, Andersen RM, Crystal SH, Fleishman JA, Golin C, Gifford A, Liu HH, Nakazono TT, Morton S, Bozzette SA, Shapiro MF, Wenger NS.

J Acquir Immune Defic Syndr. 2000 Oct 1;25(2):115-23.

PMID:
11103041
5.

Are there gender differences in starting protease inhibitors, HAART, and disease progression despite equal access to care?

Mocroft A, Gill MJ, Davidson W, Phillips AN.

J Acquir Immune Defic Syndr. 2000 Aug 15;24(5):475-82.

PMID:
11035619
6.

Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.

Verweel G, van Rossum AM, Hartwig NG, Wolfs TF, Scherpbier HJ, de Groot R.

Pediatrics. 2002 Feb;109(2):E25.

PMID:
11826235
7.

Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy.

Bouhnik AD, Préau M, Vincent E, Carrieri MP, Gallais H, Lepeu G, Gastaut JA, Moatti JP, Spire B; MANIF 2000 Study Group.

Antivir Ther. 2005;10(1):53-61.

PMID:
15751763
8.
9.

Patterns, predictors, and consequences of initial regimen type among HIV-infected women receiving highly active antiretroviral therapy.

Golub ET, Benning L, Sharma A, Gandhi M, Cohen MH, Young M, Gange SJ.

Clin Infect Dis. 2008 Jan 15;46(2):305-12. doi: 10.1086/524752.

PMID:
18171267
10.

Response to highly active antiretroviral therapy according to duration of HIV infection.

Pezzotti P, Pappagallo M, Phillips AN, Boros S, Valdarchi C, Sinicco A, Zaccarelli M, Rezza G; Italian Seroconversion Study.

J Acquir Immune Defic Syndr. 2001 Apr 15;26(5):473-9.

PMID:
11391168
11.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
12.

Factors and temporal trends associated with highly active antiretroviral therapy discontinuation in the Women's Interagency HIV Study.

Ahdieh-Grant L, Tarwater PM, Schneider MF, Anastos K, Cohen M, Khalsa A, Minkoff H, Young M, Greenblatt RM; Women's Interagency HIV Study.

J Acquir Immune Defic Syndr. 2005 Apr 1;38(4):500-3.

PMID:
15764968
13.

A comparison of exposure groups in the EuroSIDA study: starting highly active antiretroviral therapy (HAART), response to HAART, and survival.

Mocroft A, Madge S, Johnson AM, Lazzarin A, Clumeck N, Goebel FD, Viard JP, Gatell J, Blaxhult A, Lundgren JD.

J Acquir Immune Defic Syndr. 1999 Dec 1;22(4):369-78.

PMID:
10634199
14.

HIV-1 RNA, CD4 T-lymphocytes, and clinical response to highly active antiretroviral therapy.

Sterling TR, Chaisson RE, Moore RD.

AIDS. 2001 Nov 23;15(17):2251-7.

PMID:
11698698
15.

Risk factors for opportunistic illnesses in children with human immunodeficiency virus in the era of highly active antiretroviral therapy.

Ylitalo N, Brogly S, Hughes MD, Nachman S, Dankner W, Van Dyke R, Seage GR 3rd; Pediatric AIDS Clincial Trials Group Protocol 219C Team.

Arch Pediatr Adolesc Med. 2006 Aug;160(8):778-87.

PMID:
16894075
16.
17.

Immunologic and clinical responses to highly active antiretroviral therapy over 50 years of age. Results from the French Hospital Database on HIV.

Grabar S, Kousignian I, Sobel A, Le Bras P, Gasnault J, Enel P, Jung C, Mahamat A, Lang JM, Costagliola D.

AIDS. 2004 Oct 21;18(15):2029-38.

PMID:
15577624
18.

Risk of progression to AIDS and death in women infected with HIV-1 initiating highly active antiretroviral treatment at different stages of disease.

Anastos K, Barrón Y, Miotti P, Weiser B, Young M, Hessol N, Greenblatt RM, Cohen M, Augenbraun M, Levine A, Muñoz A; Women's Interagency HIV Study Collaborative Study Group.

Arch Intern Med. 2002 Sep 23;162(17):1973-80.

PMID:
12230420
19.

Effects of treated and untreated depressive symptoms on highly active antiretroviral therapy use in a US multi-site cohort of HIV-positive women.

Cook JA, Grey D, Burke-Miller J, Cohen MH, Anastos K, Gandhi M, Richardson J, Wilson T, Young M.

AIDS Care. 2006 Feb;18(2):93-100.

PMID:
16338766
20.

Clinical outcome of HIV-infected antiretroviral-naive patients with discordant immunologic and virologic responses to highly active antiretroviral therapy.

Tan R, Westfall AO, Willig JH, Mugavero MJ, Saag MS, Kaslow RA, Kempf MC.

J Acquir Immune Defic Syndr. 2008 Apr 15;47(5):553-8. doi: 10.1097/QAI.0b013e31816856c5.

PMID:
18285713

Supplemental Content

Support Center